Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Evotec SE

Biotech Giants' SG&A Expenses: A Decade of Growth

__timestampEvotec SERegeneron Pharmaceuticals, Inc.
Wednesday, January 1, 201417990000504755000
Thursday, January 1, 201525166000838526000
Friday, January 1, 2016270130001177697000
Sunday, January 1, 2017423830001320433000
Monday, January 1, 2018570120001556200000
Tuesday, January 1, 2019665460001834800000
Wednesday, January 1, 2020772380001346000000
Friday, January 1, 20211054450001824900000
Saturday, January 1, 20221561900002115900000
Sunday, January 1, 20231696100002631300000
Monday, January 1, 20242954400000
Loading chart...

Unleashing the power of data

A Tale of Two Biotech Giants: SG&A Expenses Over Time

In the competitive world of biotechnology, managing costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Regeneron Pharmaceuticals, Inc. and Evotec SE from 2014 to 2023. Regeneron, a leader in the industry, consistently outpaces Evotec in SG&A spending, reflecting its larger scale and broader market reach. In 2023, Regeneron's SG&A expenses were approximately 15 times higher than Evotec's, highlighting its significant investment in administrative and sales functions. Over the decade, Regeneron's expenses grew by over 400%, while Evotec's increased by nearly 900%, indicating rapid expansion. This data provides a fascinating insight into how these companies allocate resources to maintain their competitive edge. As the biotech landscape evolves, monitoring these trends offers valuable lessons in strategic financial management.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025